The advanced wound care market is undergoing a structural shift driven by reimbursement pressure and increasing demand for scalable solutions.
Recent CMS updates have reduced coverage for skin substitutes from ~340 products to just 18, alongside the introduction of a flat reimbursement rate (~$127/cm²). This is rapidly changing the commercial viability of high-cost biologics and accelerating the move toward synthetic and biosynthetic alternatives.
While biologic products such as EpiFix and Grafix continue to dominate the premium segment, their cost structure is becoming increasingly difficult to sustain under these conditions. In parallel, synthetic matrices such as Restrata (Acera Surgical / Solventum) and Novosorb (PolyNovo) are gaining traction by offering more predictable performance and improved scalability at lower cost points.
This shift is also reflected in recent market activity. The acquisition of Acera Surgical by Solventum highlights the strategic importance of electrospun synthetic matrices as a viable alternative to biologics in wound care.
Alongside material selection, clinical expectations are evolving. Wound-facing materials are increasingly required to perform as integrated systems, balancing fluid management, conformability, barrier function, and interaction with complex wound environments. This is where many materials start to struggle. Not at concept stage, but when exposed to real conditions, including handling, variability, and reproducibility challenges.
The Electrospinning Company supports this transition through the development and manufacture of electrospun materials designed to resemble human extracellular matrix and to deliverconsistent performance in wound-healing applications. With over ten years’ experience supplying components into regulated medical products, the company works with partners to translate material concepts into reproducible, application-ready systems.
The Mimetix® and Symatix® technology platforms use synthetic polymers or combine synthetic polymer structures with functional biomolecules, enabling the design of materials tailored for wound-facing applications where performance, consistency, and scalability are critical, while Caladrix® technology enables the coating of collagen-based sheets and membranes to further enhance functionality and application-specific performance.